公开(公告)号：US20240239886A1

公开(公告)日：2024-07-18

申请号：US18432214

申请日：2024-02-05

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Ido AMIT ,  Chamutal BORNSTEIN-OVITS ,  Adam YALIN ,  Adi MOSHE ,  Oren BARBOY ,  Assaf WEINER ,  Yonatan KATZENELENBOGEN ,  Diego JAITIN ,  Fadi SHEBAN

IPC: C07K16/28 ,  A61K35/17 ,  A61K39/00 ,  A61K45/06 ,  A61K47/64 ,  A61P35/00 ,  A61P37/04

CPC classification number: C07K16/2803 ,  A61K35/17 ,  A61K39/4611 ,  A61K39/4631 ,  A61K39/464411 ,  A61K45/06 ,  A61K47/642 ,  A61P35/00 ,  A61P37/04 ,  A61K2039/505 ,  C07K2317/565 ,  C07K2317/71

Abstract: Provided are antibodies to TREM2 and Gpnmb. Also provided are compositions comprising the antibodies and methods of using same.

公开(公告)号：US20240228521A1

公开(公告)日：2024-07-11

申请号：US18554795

申请日：2022-04-14

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： David SPERANDIO ,  Helena SHOMAR MONNGES ,  Eugene J. EISENBERG ,  Arthur MACHLENKIN

IPC: C07F9/6561 ,  A61K31/675

CPC classification number: C07F9/6561 ,  A61K31/675

Abstract: Disclosed herein are 3, 4-didehydro- and 3′-deoxy-3, 4-didehydro-compounds, and pharmaceutical compositions thereof. The 3, 4-didehydro- and 3′-deoxy-3, 4-didehydro-compounds, and pharmaceutical compositions thereof may be used in methods of treating diseases including virus-induced diseases, cancer, autoimmune diseases, immune disorders, and bacterial-associated diseases or infections, or combinations thereof. Examples of viral-induced diseases include viral infections by RNA or DNA viruses, for example SARS-CoV-2, EBV, and BKV.

公开(公告)号：US20240165027A1

公开(公告)日：2024-05-23

申请号：US18424973

申请日：2024-01-29

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Jacob KLEIN ,  Ronit GOLDBERG ,  Jasmine SEROR

IPC: A61K9/127 ,  A61K9/00 ,  A61K9/08 ,  A61K31/728 ,  A61K31/77 ,  A61K31/79 ,  A61K47/10 ,  A61K47/32 ,  A61K47/36 ,  B65D35/00 ,  B65D75/36

CPC classification number: A61K9/127 ,  A61K9/0048 ,  A61K9/08 ,  A61K31/728 ,  A61K31/77 ,  A61K31/79 ,  A61K47/10 ,  A61K47/32 ,  A61K47/36 ,  B65D35/00 ,  B65D75/36

Abstract: Formulations (e.g., solutions) comprising one or more water-soluble polymer(s), liposomes, and an aqueous carrier, are provided. The provided solutions are useful for rinsing, and/or immersing therein, a contact lens and/or in the treatment of ocular discomfort, for example, an ocular discomfort associated with a contact lens. Also provided are kits comprising the solution and a contact lens; articles-of-manufacturing comprising the solution and configured for dispending the solution; and methods utilizing the solution.

公开(公告)号：US11983607B2

公开(公告)日：2024-05-14

申请号：US18300629

申请日：2023-04-14

Applicant: QUANTUM SOURCE LABS LTD. ,  YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： Gil Semo ,  Ziv Aqua ,  Oded Melamed ,  Dan Charash ,  Serge Rosenblum ,  Barak Dayan

IPC: H01S3/042 ,  G06N10/40

CPC classification number: G06N10/40 ,  H01S3/042

Abstract: A quantum computing system, method and computer readable storage medium involve tuning a whispering-gallery mode optical resonator to support a resonance frequency associated with a transition frequency of an atom. Operation of a laser is controlled to cause the atom to be trapped adjacent the optical resonator and within the evanescent field portion. Based on an atom presence signal from an optical atom presence detector, an indication is provided that the atom is trapped adjacent the optical resonator. A frequency of a cooling laser is controlled to cool the atom, and the optical resonator is configured to define a closed loop-like mode including an evanescent field portion. The trapping laser is configured to cause the atom to be trapped adjacent the whispering-gallery mode resonator, and the cooling laser is configured to manipulate a state of the atom to thereby cool the atom.

公开(公告)号：US20240139247A1

公开(公告)日：2024-05-02

申请号：US18408385

申请日：2024-01-09

Applicant: THE MEDICAL RESEARCH INFRASTRUCTURE AND HEALTH SERVICES FUND OF THE TEL AVIV MEDICAL CENTER ,  YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： Zelig ESHHAR ,  Tova WAKS ,  Anat GLOBERSON LEVIN ,  Moran RAWET SLOBODKIN

IPC: A61K35/17 ,  A61K39/00 ,  A61K39/395 ,  A61P35/00 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783 ,  C12N5/10 ,  C12N15/63

CPC classification number: A61K35/17 ,  A61K39/001126 ,  A61K39/001129 ,  A61K39/3955 ,  A61K39/39558 ,  A61K39/4631 ,  A61P35/00 ,  C07K16/28 ,  C07K16/2896 ,  C07K16/3061 ,  C12N5/0636 ,  C12N5/10 ,  C12N15/63 ,  A61K2039/505 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/56 ,  C07K2317/569 ,  C07K2317/76 ,  C07K2319/03

Abstract: The present invention provides T-cells expressing at least two different chimeric antigen receptors, wherein one of the CARs binds specifically to CD138 and another CAR binds specifically to CD38. In particular, the present invention provides T-cells expressing two different CARs, when one CAR comprises anti-CD138 scFv and the second CAR anti-CD138 scFv. Further, the invention provides a pharmaceutical composition comprising these dual CAR T-cells and their use in treatment of cancer, in particular multiple myeloma, and methods for preparation of these cells.

公开(公告)号：US20240117386A1

公开(公告)日：2024-04-11

申请号：US17768228

申请日：2020-10-22

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Ron MILO ,  Shmuel GLEIZER ,  Niv ANTONOVSKY ,  Elad NOOR ,  Arren BAR-EVEN ,  Yehudit ZOHAR ,  Roee BEN NISSAN ,  Elad HERZ ,  Yinon Moise BAR-ON

IPC: C12P1/04 ,  C07K14/195 ,  C12N1/20 ,  C12N9/02 ,  C12N9/12 ,  C12N9/88

CPC classification number: C12P1/04 ,  C07K14/195 ,  C12N1/20 ,  C12N9/0008 ,  C12N9/1205 ,  C12N9/88 ,  C12Y102/02001 ,  C12Y207/01019 ,  C12Y401/01039 ,  C12Y402/01001

Abstract: A recombinant bacteria which is genetically modified to express formate dehydrogenase (FDH), phosphoribulokinase (prk) and Ribulose-Bisphosphate Carboxylase/oxygenase (RuBisCo) is disclosed. The bacteria may be modified to be autotrophic.

公开(公告)号：US20240069042A1

公开(公告)日：2024-02-29

申请号：US18387593

申请日：2023-11-07

Applicant: NeuroQuest Ltd. ,  Yeda Research and Development Co. Ltd. at the Weizmann Institute of Science

Inventor： Xin Huang ,  Yihan Li ,  James Doecke ,  Michal Eisenbach-Schwartz ,  Baijun Gu

IPC: G01N33/68 ,  G01N33/58

CPC classification number: G01N33/6896 ,  G01N33/582 ,  G01N2800/2821

Abstract: Compositions and kits for diagnosing and prognosing Alzheimer's Disease (AD) in a human patient include a binding agent such as a monoclonal antibody for a biomarker conjugated to a detectable moiety such as a fluorophore, wherein the biomarker is chosen from CD11c, CD59, CD91, and CD163 and other phagocytosis-related molecules. Further compositions and kits employ panels of fluorophore-conjugated monoclonal antibodies for biomarkers including scavenger receptors. Methods for determining the relative expression of biomarkers, diagnosing AD, and determining the efficacy of AD therapeutic candidates such as phagocytosis-promoting agents and scavenger receptor agonists also appear.

公开(公告)号：US20240065988A1

公开(公告)日：2024-02-29

申请号：US18376875

申请日：2023-10-05

Applicant: Yeda Research and Development Co. Ltd. ,  Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.

Inventor： Alon CHEN ,  Juan Pablo LOPEZ

IPC: A61K31/135 ,  A61K31/216 ,  A61P25/24

CPC classification number: A61K31/135 ,  A61K31/216 ,  A61P25/24

Abstract: A method of treating a psychiatric disorder in a subject in need thereof is disclosed. The method comprising administering to the subject a therapeutically effective amount of an N-methyl-D-aspartate (NMDA) receptor antagonist and a therapeutically effective amount of a KCNQ channel activator. Pharmaceutical compositions comprising an NMDA receptor antagonist and a KCNQ channel activator are also disclosed.

公开(公告)号：US11884727B2

公开(公告)日：2024-01-30

申请号：US17186960

申请日：2021-02-26

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Michal Eisenbach-Schwartz ,  Kuti Baruch ,  Neta Rosenzweig

IPC: C07K16/28 ,  A61K39/395 ,  A61P25/28 ,  A61P37/02 ,  A61K38/00 ,  A61K38/14 ,  A61K45/06 ,  A61K31/404 ,  A61K31/7068 ,  A61K33/36 ,  A61K38/16 ,  A61K38/18 ,  A61K38/20 ,  A61K31/4155 ,  A61K38/02 ,  A61K39/00

CPC classification number: C07K16/2803 ,  A61K31/404 ,  A61K31/4155 ,  A61K31/7068 ,  A61K33/36 ,  A61K38/00 ,  A61K38/005 ,  A61K38/02 ,  A61K38/14 ,  A61K38/168 ,  A61K38/18 ,  A61K38/208 ,  A61K39/395 ,  A61K39/3955 ,  A61K39/39541 ,  A61K45/06 ,  C07K16/2818 ,  C07K16/2827 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2121/00 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/75 ,  C07K2317/76 ,  A61K38/208 ,  A61K2300/00 ,  A61K33/36 ,  A61K2300/00 ,  A61K31/404 ,  A61K2300/00 ,  A61K31/4155 ,  A61K2300/00 ,  A61K31/7068 ,  A61K2300/00

Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.

公开(公告)号：US20240026357A1

公开(公告)日：2024-01-25

申请号：US18221914

申请日：2023-07-14

Applicant: Yeda Research and Development Co. Ltd. ,  miCure Therapeutics Ltd.

Inventor： Alon CHEN ,  Sharon MANASHIROV ,  Andres Pablo MONTEFELTRO

IPC: C12N15/113 ,  A61K47/55 ,  A61K47/54 ,  A61P25/24

CPC classification number: C12N15/113 ,  A61K47/55 ,  A61K47/548 ,  A61P25/24 ,  C12N2310/141

Abstract: A composition of matter comprising a synthetic miR-135 molecule comprising a nucleic acid sequence of a miR-135b as set forth in SEQ ID NO: 37, and a complementary strand as set forth in SEQ ID NO: 40 is disclosed. A conjugate comprising a composition of matter comprising a synthetic miR-135 molecule and a cell-targeting moiety is also disclosed.